Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Medicine & Life Sciences

• semaglutide 100%
• Liraglutide 80%
• Type 2 Diabetes Mellitus 43%
• Placebos 39%
• Glucagon-Like Peptide-1 Receptor 9%
• Therapeutics 8%
• Weight Loss 6%
• CI 22 5%
• Sodium-Glucose Transporter 2 Inhibitors 5%
• Drug Repositioning 5%
• Symporters 5%
• Pharmaceutical Preparations 4%
• Glucagon-Like Peptide 1 4%
• Safety 4%
• Continuity of Patient Care 4%
• Metformin 4%
• Glycated Hemoglobin A 4%
• Subcutaneous Injections 4%
• Registries 3%
• Clinical Trials 2%
• Weights and Measures 2%
• Glucose 2%